MedTrace Logo

Cardiac Assessment by PV Loop in IPAH and Scleroderma PAH

NCT04610788 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 43

Last updated 2026-01-09

No results posted yet for this study

Summary

This observational study is being done to understand why people with scleroderma can develop pulmonary arterial hypertension (high blood pressure in the lungs, abbreviated PAH) and a weak heart muscle (heart failure). The study will also help the investigators understand why people with PAH from an unknown cause (called idiopathic PAH, or IPAH) can also develop a weakened heart muscle. The response of the right side of the heart or right ventricle (RV) to standard PAH therapy in scleroderma-associated PAH and in IPAH will be assessed. Blood and tissue samples will be collected from research participants during participants' normal standard of care procedures. People with scleroderma-associated PAH or idiopathic cause (IPAH) who need a right heart catheterization may join this study.

Conditions

  • Scleroderma
  • Pulmonary Artery Hypertension

Sponsors & Collaborators

Principal Investigators

  • Paul Hassoun, MD · Johns Hopkins University

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-15
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04610788 on ClinicalTrials.gov